Nebulized step-down budesonide vs. fluticasone in infantile asthma: A retrospective cohort study

The United States Food and Drug Administration has approved budesonide in infantile asthma but nebulization of infants under budesonide has the risk of relapse of asthma. The objective of the present study was to compare the effectiveness and safety of fluticasone step-down treatment with budesonide...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and therapeutic medicine 2020-03, Vol.19 (3), p.1665-1672
Main Authors: Wu, Zhimin, Bian, Xiangli, Hui, Lei, Zhang, Jinping
Format: Article
Language:English
Subjects:
Asthma
Babies
Cohort analysis
Drug approval
Enrollments
Glucocorticoids
Hormones
Hospitals
Infants
Inhalers
Lung diseases
Nursing
Pediatrics
Pulmonary function tests
Statistical analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The United States Food and Drug Administration has approved budesonide in infantile asthma but nebulization of infants under budesonide has the risk of relapse of asthma. The objective of the present study was to compare the effectiveness and safety of fluticasone step-down treatment with budesonide step-down treatment in infantile asthma. The data of 778 infants with confirmed asthma were included in the analysis. Infants who had received nebulized 500 µg budesonide twice daily for 6 weeks followed by 250 µg budesonide twice daily for 6 weeks were included in the BS group (n=389), while infants who had received nebulized 250 µg fluticasone twice daily for 6 weeks followed by 125 µg fluticasone twice daily for 6 weeks were included in the FC group (n=389). The data of lung function tests and a safety study were collected and analyzed. Budesonide treatment achieved a reduced specific airway resistance (sRaw; 1.28±0.11 vs. 1.21±0.10 kPa/sec; P
ISSN:1792-0981
1792-1015
DOI:10.3892/etm.2019.8401